Novel oral fast-disintegrating drug delivery devices with predefined inner structure fabricated by Three-Dimensional Printing

Yu, Deng‐Guang; Shen, Xia-Xia; Branford-White, Christopher; Zhu, Li‐Min; White, Kenneth; Xiang, Yang

doi:10.1211/jpp/61.03.0006

Cited by 28 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yu et al (2007) employed the method to construct a methacrylic or ethylcellulose matrix tablet to achieve a linear release of diclofenac sodium (59). The ability to construct complex formulation designs, even ones with loose powders in its inner regions, was also demonstrated using PB 3D printing (37,61). A PB 3D printed core-shell structure containing the drug pseudoephedrine hydrochloride was also constructed and drug release was shown to be nearly at zero order (60).…”

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

“…Recently, this technique has also been used in the fabrication of fast disintegrating tablets (61). A pioneering example of the commercialisation of powder based technology is the development of ZipDose ® , the first FDA approved 3D printed tablet.…”

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

“…Post-printing processes must also be carried out to remove excess powders accumulated during printing, confining its use to specialized powder laboratories and implicate significant wastage. The high porosity of structures resulting from PB 3D printing is associated with poor mechanical resistance and high friability (36,61). Furthermore, since PB 3D printing is limited by the thickness of the powder layer, achieving high resolution objects can be challenging (45).…”

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

“…FDM 3D printing allowed fabrication of partially hollow tablets (d) (77). PB 3D printing constructed shell-core structure by selective deposition of binder solution in the shell domains (e) (36) and by adding internal supporting walls, tablet's physical resistance can be improved (f) (61). PB 3D printing was also utilized to build doughnut shape tablets with linear drug release (g) (85).…”

Section: Figmentioning

confidence: 99%

See 3 more Smart Citations

Emergence of 3D Printed Dosage Forms: Opportunities and Challenges

et al. 2016

View full text Add to dashboard Cite

The recent introduction of the first FDA approved 3D-printed drug has fuelled interest in 3D printing technology, which is set to revolutionize healthcare. Since its initial use, this rapid prototyping (RP) technology has evolved to such as extent that it is currently being used in a wide range of applications including in tissue engineering, dentistry, construction, automotive and aerospace. However, in the pharmaceutical industry this technology is still in its infancy and its potential yet to be fully explored. This paper presents various 3D printing technologies such as stereolithographic, powder based, selective laser sintering, fused deposition modelling and semi-solid extrusion 3D printing. It also provides a comprehensive review of previous attempts at using 3D printing technologies on the manufacturing dosage forms with a particular focus on oral tablets. Their advantages particularly with adaptability in the pharmaceutical field have been highlighted, including design flexibility and control and manufacture which enables the preparation of dosage forms with complex designs and geometries, multiple actives and tailored release profiles. An insight into the technical challenges facing the different 3D printing technologies such as the formulation and processing parameters is provided. Light is also shed on the different regulatory challenges that need to be overcome for 3D printing to fulfil its real potential in the pharmaceutical industry.

show abstract

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

Section: A Stereolithographic 3d Printing (Sla)mentioning

confidence: 99%

Section: Figmentioning

confidence: 99%

See 2 more Smart Citations

Emergence of 3D Printed Dosage Forms: Opportunities and Challenges

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Dissolving both the poorly water-soluble APIs and the polymeric excipients in a common solvent or a mixed solvent system and then evaporating the solvent to obtain an ASD is a widely utilised process. Many different technologies have been developed to remove the solvents more quickly and completely, such heat drying, vacuum drying, using hot air or nitrogen, spray-drying, and using supercritical fluids [176][177][178]. Electrospinning is advantageous here because its evaporation rate is extremely fast, whereas with the other processes it is often very hard to remove all the organic solvents in a rapid manner.…”

Section: Technical Advantagesmentioning

confidence: 99%

Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review

Williams

et al. 2018

Journal of Controlled Release

Self Cite

250

156

View full text Add to dashboard Cite

The development of oral dosage forms for poorly water-soluble active pharmaceutical ingredients (APIs) is a persistent challenge. A range of methods has been explored to address this issue, and amorphous solid dispersions (ASDs) have received increasing attention. ASDs are typically prepared by starting with a liquid precursor (a solution or melt) and applying energy for solidification. Many techniques can be used, with the emergence of electrospinning as a potent option in recent years. This method uses electrical energy to induce changes from liquid to solid. Through the direct applications of electrical energy, electrospinning can generate nanofiber-based ASDs from drug-loaded solutions, melts and melt-solutions. The technique can also be combined with other approaches using the application of mechanical, thermal or other energy sources. Electrospinning has numerous advantages over other approaches to produce ASDs. These advantages include extremely rapid drying speeds, ease of implentation, compatibility with a wide range of active ingredients (including those which are thermally labile), and the generation of products with large surface areas and high porosity. Furthermore, this technique exhibits the potential to create so-called 'fifth-generation' ASDs with nanostructured architectures, such as core/shell or Janus systems and their combinations. These advanced systems can improve dissolution behaviour and provide programmable drug release profiles. Additionally, the fiber components and their spatial distributions can be precisely controlled. Electrospun fiber-based ASDs can maintain an incorporated active ingredient in the amorphous physical form for prolonged periods of time because of their homogeneous drug distribution within the polymer matrix (typically they comprise solid solutions), and ability to inhibit molecular motion. These ASDs can be utilised to generate oral dosage forms for poorly water-soluble drugs, resulting in linear or multiple-phase release of one or more APIs. Electrospun ASDs can also be exploited as templates for manipulating molecular self-assembly, offering a bridge between ASDs and other types of dosage forms. This review addresses the development, advantages and pharmaceutical applications of electrospinning for producing polymeric ASDs. Material preparation and analysis procedures are considered. The mechanisms through which performance has been improved are also discussed.

show abstract